Source: http://globenewswire.com/
SAN RAMON, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's GALE-301 and GALE-302 clinical programs were presented at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland. The data presented was on the primary vaccine series (PVS) from a randomized Phase 1b trial with GALE-301 (E39) and GALE-302 (E39' – variant of E39; previously named J65) that are folate binding protein-derived (FBP) peptides.
Poster #166 (abstract #156) entitled, "Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine," details the results of a randomized trial comparing three PVS sequences of E39 and E39' in ovarian and breast cancer patients to optimize the ex vivo immune responses, local reactions (LR), and delayed type hypersensitivity (DTH) reactions. This preliminary analysis revealed both agents are immunogenic and well tolerated with no differences in toxicities between PVS sequences. The study demonstrates that the in vivo immune response is enhanced with the use of the attenuated E39' (GALE-302) after E39 (GALE-301). The optimal vaccination sequence utilizing three inoculations of GALE-301 followed by three inoculations of GALE-302 produced the most prominent and statistically significant LR and DTH responses.
Read more: http://globenewswire.com/news-release/2015/11/09/785131/10155652/en/Galena-Biopharma-Presents-GALE-302-Preliminary-Immunologic-Data-Optimizing-GALE-301-at-the-Society-for-Immunotherapy-of-Cancer-SITC-30th-Anniversary-Annual-Meeting.html